Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up

Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jul;19(7):905-9. doi: 10.1007/s00192-007-0548-9. Epub 2008 Jan 19.

Abstract

The aim of this trial was to examine the effects after 2 years of a single intravesical botulinum toxin-A injection (BTX-A). This prospective, observational study was conducted using urodynamic measurements and quality of life (QoL) assessment to document the effect after 2 years of a single 100 I.U. injection of BTX-A into the vesical detrusor muscle. Twenty-six patients were followed up for 2 years after a first intravesical BTX-A injection. Of these 26 patients, one was a primary failure, three were lost to follow-up, and 11 patients had a repeated injection at 5-26 months (one patient had a third injection). Seven of the remaining 11 patients in the single injection group were recommended repeated injection or another treatment, and four required no other treatment. In conclusion, 2 years after a single BTX-A injection statistically significant differences in urodynamics and an improvement in QoL could still be demonstrated.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Botulinum Toxins, Type A / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Neuromuscular Agents / therapeutic use*
  • Quality of Life
  • Urinary Bladder, Overactive / drug therapy*

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A